Molbio Diagnostics shares made a strong market debut on Monday, August 17, 2026, listing at ₹980 per share on both NSE and BSE, representing a premium of 21.43% over the IPO issue price of ₹807 per share. According to reports from The Hindu BusinessLine, the stock further surged 24.16% to ₹1,002.05 during trading, with the company commanding a market valuation of ₹10,875.77 crore. The ₹940 crore IPO was subscribed 70.26 times during the three-day bidding period, with the company's market capitalisation standing at ₹10,875.77 crore according to BSE data. The stock opened at ₹980 on both exchanges, surging ₹173 from the IPO price.
Investors who received Molbio Diagnostics IPO allotment made ₹17,640 per lot, taking the total value of their investment to ₹3,114 as per the listing price on NSE. The lot structure consisted of 18 shares with a total cost of ₹14,526 at the upper end of the price band. The strong subscription performance across all categories showed the QIB portion subscribed 186.39 times, while the NII category achieved 49.80 times subscription and the retail portion 12.96 times. The company had raised ₹281.5 crore from anchor investors including Goldman Sachs (₹30 crore), BlackRock Global Funds (₹20 crore), and IFC (₹20 crore). The issue was priced at ₹768 to ₹807 per share with allotment finalised on Thursday, 13 August. As per The Economic Times, the company's profit after tax (PAT) increased 18% to ₹164 crore in FY26, up from ₹138.58 crore in the previous financial year, demonstrating improved profitability.
The ₹940 crore IPO comprises a ₹200 crore fresh issue for R&D infrastructure and Centre of Excellence under subsidiary Bigtec, while the ₹739.70 crore OFS portion goes to existing shareholders selling part of their stake. As per The Economic Times, the company plans to utilise ₹106 crore from the fresh issue proceeds towards capital expenditure for setting up infrastructure for an R&D facility, Centre of Excellence and connected office space. Another ₹72 crore will be deployed towards the purchase of plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit, while the remaining funds will be used for general corporate purposes. This strategic expansion will strengthen the company's manufacturing capabilities and R&D capabilities across multiple locations. The estimated utilisation of IPO proceeds stands at ₹205.93 crore, with an additional ₹80.81 crore planned for plant, machinery and equipment for manufacturing facilities in Goa and Visakhapatnam.
Market sentiment for Molbio Diagnostics IPO remained robust ahead of its debut, with grey market premium (GMP) standing at ₹116-130, indicating a potential listing price of ₹927-930, representing a premium of around 14.87% over the issue price of ₹807. According to grey market sources, the last grey market premium on Monday morning was ₹116, suggesting the stock could list at a 14.37% premium at ₹927. However, the actual listing price of ₹980 delivered a 21.43% premium, demonstrating the stock's ability to outperform even optimistic market expectations. The strong grey market performance exceeded expectations, as the actual listing price of ₹980 delivered a 21.43% premium, with the stock rallying up to 6% to ₹1,044 on Monday after the strong debut, surpassing grey market expectations which had indicated a listing premium of around 15%.
Molbio Diagnostics Ltd, incorporated in October 2000, is a global point-of-care molecular diagnostics company engaged in offering molecular testing for 30 diseases, including tuberculosis, HPV, HIV, COVID and Hepatitis B and C. The company operates as a WHO-recommended TB testing technology provider with patents across more than 100 countries. Its 'Truenat' platform, patented in more than 100 countries for diagnosis of multiple infectious and non-communicable diseases, is a point-of-care polymerase chain reaction (PCR) platform that can be deployed in resource-limited settings and facilitates decentralised diagnosis within an hour. As of March 31, 2026, over 12,500 Truenat devices were installed across more than 90 countries, with revenue primarily generated from devices and recurring sales of proprietary Truenat test kits. In FY26, devices, test kits and other products contributed 14.53%, 73.98% and 11.49% of total sales respectively, while exports accounted for 9.6% of revenue. The company has also expanded beyond molecular diagnostics into radiology, digital pathology, and breast health screening through subsidiaries and strategic partnerships, supported by its research and development capabilities.
